Navigation Links
Pharmasset Reports Positive Results from its HCV Clinical Programs
Date:1/6/2011

a preliminary proof-of-concept for an all oral, nucleotide combination regimen."Calendar Year 2011 Anticipated Milestones:-- Pharmasset expects to report SVR12 data from its ongoing phase 2b trial with PSI-7977 in HCV genotype 2/3 patients in the second quarter of 2011

-- Pharmasset expects to report the 12 week interim analysis from its PSI-7977 Phase 2b genotype 1 arms in the second quarter of 2011

-- Pharmasset expects to initiate a 24 week Phase 2b trial with PSI-7977 in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2 study with PSI-7977 and PSI-938 in mid-2011

-- Pharmasset plans to file an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a phase 3 program with RG7128 in 2011

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have four clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 /PRNewswire/ ... today, which integrates with HealthKit in iOS 8 and ... with their doctors. The app harnesses native iOS technologies ... patients to maintain a robust connection with their doctors ... wearable health devices and the data they collect is ...
(Date:9/30/2014)... Sept. 30, 2014  Based on its recent ... & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), ... 2014 North American Frost & Sullivan Award for ... along with a focus on innovation and improving ... in tissue-based cancer diagnostic solutions for patients worldwide. ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... Neb., May 15 Creighton Medical Laboratories, based at ... announced today that it has become the first clinical ... testing method for cancer. The method, called SNP array ... to study cancer for several years. However, Creighton Medical ...
... Case Demonstrating RenalGuard To Be PresentedFRANKLIN, Mass., May ... PLCSF), a company focused on innovative cardiac and ... will demonstrate its RenalGuard System(TM) at EuroPCR, the ... Cardiovascular Interventions (EAPCI), May 19-22, 2009, in Barcelona, ...
Cached Medicine Technology:Creighton Medical Laboratories First to Offer New Cancer Test 2Creighton Medical Laboratories First to Offer New Cancer Test 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 2PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 3PLC Medical Systems to Demonstrate RenalGuard(R) at EuroPCR 2009 4
(Date:9/30/2014)... and cardiac muscles contain few stem cells, heart ... heart attack. Now Tel Aviv University researchers are ... tissue engineering. , Dr. Tal Dvir and his ... Biotechnology, Department of Materials Science and Engineering, and ... sophisticated micro- and nanotechnological tools ranging in ...
(Date:9/30/2014)... 2014 A new report launched today by ... Longitudinal Study on Ageing) conducted by academics from ... Dublin, Ireland, has highlighted the serious, complex and ... disability population. , The IDS-TILDA study is the ... the only one in the world with the ...
(Date:9/30/2014)... MyServer2Go.com made an announcement recently that ... this year for its quality VPS solution, reliable support ... MyServer2Go.com is a professional and targeted website which reviewed ... announcement will help webmasters find the best VPS hosting ... http://www.arvixe.com ) is one of the fastest-growing and most ...
(Date:9/30/2014)... Wellington, New Zealand (PRWEB) September 30, 2014 ... offers the potential to improve breast cancer risk ... risk, according to a study published in Breast ... article, “Digital mammographic density and breast cancer risk: ... methods,” demonstrates a strong connection between breast density ...
(Date:9/30/2014)... home surrounded by loved ones comes too late for ... change the process so that more patients may die ... the Frances Payne Bolton School of Nursing at Case ... million grant from the National Institute of Nursing Research ... Aggressiveness of End of Life Cancer Care," will contribute ...
Breaking Medicine News(10 mins):Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4Health News:Arvixe Is Named Best VPS Hosting by MyServer2Go.com 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 2Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 3Health News:Mammographic Density Offers Potential to Improve Prediction of Breast Cancer Risk and Development of Personalized Screening 4Health News:CWRU researchers receives $2.06 million to study how patients make end-of-life decisions 2
... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
... , SUNDAY, April 3 (HealthDay News) -- There,s a ... women, but it depends on their body weight, researchers report. ... smokers who were not obese, but this strong association was ... study. Researchers analyzed data from 76,628 women, aged 50 ...
... test believe it is the most accurate yet in ... asbestos. Study results of this aptamer proteomic technology were ... April 2-6. In a blinded test performed under ... Research Network Biomarker Discovery Lab, the proteomic assay could ...
... NYU Langone Medical Center have investigated a novel protein ... can accurately identify proteins secreted from cancerous tumors caused ... American Association for Cancer Research 102nd Annual Meeting 2011 ... performed under the sponsorship of the National Cancer Institute,s ...
... Amanda Gardner HealthDay Reporter , SUNDAY, April 3 ... a new valve in a damaged heart is as good ... risk of stroke, researchers reported Sunday. Transcatheter ... in the heart via an artery in the leg or ...
... Reporter , SATURDAY, April 2 (HealthDay News) -- Men taking ... the risk of a heart attack or stroke, a small, ... 5 percent increase in the thickness of the large artery ... to the brain, the researchers from Emory University found. ...
Cached Medicine News:Health News:Clumsy kids who don't 'grow out of it' 2Health News:Study Links Smoking, Breast Cancer in Older Women 2Health News:Protein test detects early-stage, asbestos-related pulmonary cancer 2Health News:New test detects early-stage, asbestos-related pulmonary cancer 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 2Health News:Minimally Invasive Heart-Valve Procedure Shows Promise: Study 3Health News:Study Hints at Link Between Antidepressants and Heart Trouble 2Health News:Study Hints at Link Between Antidepressants and Heart Trouble 3
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... The Equalizer With 384 Well Plate ... the revolutionary features of the original Equalizerexpandable and ... autoclavable components, and in-lab calibration capabilities. In addition, ... tips down to 4.5mm for loading and accessing ...
Packaging: Set includes: Eight-channel pipette (10.8 mm with 0.5-5.0 μl capacity) 25 PrismStrip 96 tips with rack 2 FlexPlates with a holder...
The Biopette E has a comfortable, ergonomic design. Fully motorized piston drive. Virtually eliminates pipetting forces. User-friendly operator interface. Simple, precise volume setting. Rechargelabl...
Medicine Products: